Lexaria Bioscience Corp. LEXX Archives - Page 34 of 39

FridayNov 12, 2021 1:20 pm

Lexaria Bioscience Corp. (NASDAQ: LEXX) Embarks on its Most Ambitious Hypertension Clinical Study Yet: HYPER-H21-4

Lexaria has embarked on its HYPER-H21-4 study, its fourth hypertension clinical study, and it's most ambitious yet This study builds on the HYPER-H21-1 and HYPER-H21-2 findings, as well as the HYPER-H21-3 study that is set to begin dosing in mid-November 2021 Lexaria’s goal is to pursue regulatory approval for its proprietary DehydraTECH-CBD for potential use as a treatment for high blood pressure Study protocols are being readied for submission to the IRB, and approval is expected by January 2022 Lexaria Bioscience (NASDAQ: LEXX) has, so far in 2021, embarked on several studies geared towards evaluating its proprietary DehydraTECH(TM) CBD for…

WednesdayNov 10, 2021 11:15 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands 2022 R&D Programs to Evaluate Potential Treatment Options for Alzheimer’s and Diabetes

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced its plans for several new and ongoing DehydraTECH(TM)-applied R&D programs for 2022. According to the update, the studies mentioned in the announcement represent only a fraction of Lexaria's 2022 work programs. “Calendar 2022 will continue to see significant milestones in utilizing DehydraTECH-CBD for investigation of heart disease and hypertension; and separately, for oral nicotine delivery as an alternative to smoking,” said Chris Bunka, CEO of Lexaria Bioscience Corp. “We are delighted to announce that DehydraTECH as an enhanced drug delivery platform will also be evaluated for…

WednesdayNov 03, 2021 12:27 pm

Lexaria Bioscience Corp. (NASDAQ: LEXX) Commences New Animal Study Evaluating Patented DehydraTECH(TM) Technology’s Efficacy in Reducing/Inhibiting Seizure Activity; Strengthens IP Portfolio

Lexaria recently announced the commencement of EPIL-A21-1, an animal study to evaluate whether DehydraTECH-CBD has similar or superior efficacy in reducing or inhibiting seizure activity compared to FDA-approved seizure drug, Epidiolex The study will also compare DehydraTECH-CBD to generic CBD EPIL-A21-1 has entered early-stage preparatory work, with results expected in Q3 2022 Lexaria received new patent awards in Mexico and Japan, strengthening its IP portfolio to 23 granted patents Lexaria Bioscience (NASDAQ: LEXX), the drug delivery platform innovator behind the disruptive, patented DehydraTECH(TM) technology, recently announced it had commenced an important new animal study, EPIL-A21-1 (https://ibn.fm/LG7O6). EPIL-A21-1, which will be…

WednesdayNov 03, 2021 11:41 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) to Expand Hypertension Clinical Program Through Most Ambitious Study to Date

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced a significant new study to expand its hypertension clinical program. In addition, the company provided updates on three ongoing human clinical studies evaluating its proprietary DehydraTECH-CBD for potentially treating hypertension and heart disease. “HYPER-H21-4 is the most ambitious study Lexaria has ever undertaken and is enabled from the successful outcomes from our other 2021 human hypertension studies,” said Lexaria CEO Chris Bunka in the news release. “Outcomes from this study could support Lexaria's goals related to pursuit of regulatory approvals for DehydraTECH-CBD for potential use as…

MondayNov 01, 2021 1:32 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Begins R&D Program Comparing DehydraTECH-CBD with Generic CBD, Epidiolex

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has begun a new study, EPIL-A21-1,designed to evaluate whether its DehydraTECH(TM)-CBD (“CBD”) indicates superior ability to reduce seizure activity compared to both generic cannabidiol and Epidiolex. Epidiolex is the only CBD medication approved by the U.S. Food and Drug Administration (“FDA”) for the treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome, two rare and severe forms of pediatric epilepsy. Among those involved in the study are respirology and neurobiology experts. According to the announcement, the team of investigators will carefully analyze how DehydraTECH-CBD compares with Epidiolex in treating seizures.…

FridayOct 29, 2021 1:07 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Earns Coverage for DehydraTECH(TM)’s Potential Market Reach, Multiple Uses

Lexaria Bioscience Corp. (NASDAQ: LEXX) was recently part of coverage by Zacks Small-Cap Research analysts based on its market potential. Zacks, which focuses its coverage on small and micro-cap companies it regards as under-followed or under-valued by the broader market in an effort to benefit investors as well as worthy innovators, valued the company at $15 per share. The valuation was based on the company’s portfolio supporting Lexaria’s patented DehydraTECH(TM) consumption and the multiple potential uses of the technology. The technology is also relatively low-cost, with the capacity to produce up to 400,000 consumer packaged goods through existing manufacturer relationships.…

TuesdayOct 26, 2021 9:00 am

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Addresses the Needs of Medical THC Users

Lexaria’s THC absorption animal study yielded promising results on the patented DehydraTECH(TM) technology It showed that the technology required a shorter time to deliver the same THC levels than concentration-matched controls Lexaria believes that through DehydraTECH, it is meeting the needs of medical THC users with its rapid delivery, increased overall THC delivery and high brain tissue delivery Lexaria Bioscience's (NASDAQ: LEXX) just-concluded oral tetrahydrocannabinol (“THC”) absorption animal study, THC-A21-1, yielded promising results on the effectiveness of the company’s patented DehydraTECH(TM) drug delivery technology. The study, performed by a leading, independent laboratory, involved 20 male Sprague Dawley rats split into…

FridayOct 22, 2021 9:00 am

New Study Underscores Rapidity of Oral Drug Bio-delivery Using Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Technology as an Alternative to Smoking and Vaping

Oral drug delivery innovator Lexaria Bioscience is focused on providing alternatives to smoked or inhaled tobacco and cannabis products to help consumers reduce the threat to their lungs Lexaria’s patented technology — DehydraTECH(TM) — is a solution that processes active pharmaceutical ingredients into a powder or liquid form that can then be ingested with less harm than inhalation, while providing rapidity similar to inhalation substances DehydraTECH has previously shown the ability to move CBD into test subjects’ bloodstreams up to 20-fold higher than standard generic formulations New testing shows that DehydraTECH can similarly deliver THC to test subjects’ bloodstreams at…

WednesdayOct 20, 2021 11:05 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Study Reveals Effectiveness of Proprietary Drug-Development Tech

Lexaria Bioscience (NASDAQ: LEXX), developers of the revolutionary DehydraTECH(TM) drug-delivery technology, has released study results focused on THC-A21-1, a THC oral format. According to the announcement, the study showed that Lexaria’s DehydraTECH THC solution delivers THC levels to blood plasma an estimated three times faster than standard MCT-based THC. Based on study results, it took only 15 minutes using oral ingestion of the substance to reach THC levels comparable to those reached in 45 minutes using "coconut-oil" formulations. As the THC left the system at the six-hour mark, levels were comparable and demonstrated the fast-on, fast-off performance. The DehydraTECH results are timely…

WednesdayOct 20, 2021 9:26 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Inches Closer to Revolutionizing the Nicotine Industry with its Alternative Nicotine Delivery

Lexaria’s recent animal study on its patented DehydraTECH(TM) technology on nicotine absorption yielded ground-breaking results This study builds on an earlier 2018 study that demonstrated effective delivery of nicotine to the central nervous system in a rodent study The study’s success will serve as the foundation for a human trial that will compare the DehydraTECH-nicotine pouch performance to leading brands Zacks Small Cap Research recently did a deep dive on Lexaria Bioscience (NASDAQ: LEXX) and its contribution to alternative nicotine delivery. Its evaluation acknowledged that the global tobacco market is currently valued at $818 billion, mainly sustained by over 1.1…

Site Search

Company Search

Tag: Lexaria Bioscience Corp. LEXX